Cash and cash equivalents were $208.5 million as of June 30, 2025, compared to $302.1 million as of December 31, 2024. Wave expects that its current cash and cash equivalents will be sufficient to fund operations into 2027. Potential future milestones and other payments to Wave under its GSK collaboration are not included in its cash runway.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Optimistic Buy Rating for Wave Life Sciences Driven by Promising AATD Treatment Developments and RNA Editing Technology Potential
- Wave Life Sciences initiated with an Outperform at Oppenheimer
- Wave Life Sciences initiated with a Buy at Citi
- Wave Life Sciences: Promising RNA Therapies and Strong Financial Position Support Buy Rating
- Wave Life Sciences: Promising RNA Editing Developments and Positive Stock Outlook